Summary

for people ages 18 years and up (full criteria)
at Irvine, California and other locations
study started
estimated completion

Description

Summary

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

Official Title

A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis

Keywords

PsoriasisApremilastBMS-986165

Eligibility

For people ages 18 years and up

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Plaque psoriasis for at least 6 months
  • Moderate to severe disease
  • Candidate for phototherapy or systemic therapy

Exclusion Criteria:

  • Other forms of psoriasis
  • History of recent infection
  • Prior exposure to BMS-986165 or active comparator

Other protocol defined inclusion/exclusion criteria may apply

Locations

  • University California at Irvine Dermatology Clinical Research Centeraccepting new patients
    IrvineCalifornia92697United States
  • First OC Dermatology & Belle-Aimee Skincare Clinic Fountain Valleyaccepting new patients
    Fountain ValleyCalifornia92708United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Investigator Inquiry Form
FDA Safety Alerts and Recalls
ID
NCT03624127
Phase
Phase 3
Study Type
Interventional
Last Updated